Janssen Oncology: Our purpose
Our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those with cancer begins with a very considered step forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of Purpose®.
We fiercely believe cancer is a challenge we can collectively overcome. Find out more on our congress hub:
Please note, congress material is in parts promotional and is intended for European, Middle Eastern and African healthcare professionals only. Should you wish to proceed please enter login details.
For more than 30 years, we have been leaders in oncology research[1]
In that time, we have designed, developed and delivered treatments that change what it means to have, and to treat, cancer.[2][3][4][5][6][7] We have years of outstanding legacy in haematological malignancies and prostate cancer. In fact, in the last 7 years, we have launched five new oncology treatments in Europe.[2][3][4][5][6][8][9][10][11] What's more, we have four more treatments currently under investigation in phase III clinical trials.[12][13][14][15][16]
Over a million cancer patients have been treated with our medicines worldwide.[17][18][19][20]
At Janssen Oncology, we are taking science from where it is to where it has never been before, through targeted transformation[21]
We recognise that every cancer is different, each possessing unique challenges along the way.[22] But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference.
Cancer brings devastation, but we are striving to make meaningful change. Find out more about our areas of focus:
Multiple myeloma
Bladder cancer
Prostate cancer
Lung cancer
Discover precisely focused information on:
The diagnosis and management of rare haematological malignancies: Waldenström's macroglobulinaemia and mantle cell lymphoma
The hidden threat of EGFR exon 20 insertion mutations in NSCLC and the importance of testing
Start seeing your patients' tumour drivers more clearly: the role of FGFR
Our first responsibility is to the patients suffering from cancer, wherever they are in their own personal journey
Worldwide in 2020 there were an estimated 19.3 million new cancer cases and 9.9 million deaths.[23] Cancer brings devastation. Patients, their families, and the entire oncology community deserve meaningful change. At Janssen Oncology, we consistently integrate their perspectives into everything we do. But we don’t just listen, we use insight to create solutions that make a truly meaningful difference.
We place people front and centre and are committed to delivering high quality medical education
To help us achieve this we are privileged to have the support and participation of internationally renowned experts who form our scientific committee and faculties. Their involvement ensures we continue to provide clinically relevant and balanced education.
To find out more about our solid tumour medical education hub, visit The OME Forum
To find out more about our haematology education hub, visit The HME Forum
EGFR, epidermal growth factor receptor. FGFR, fibroblast growth factor receptor. NSCLC, non-small cell lung cancer.
Date of preparation: June 2021 | CP-232494